WXNC in the News

Featured

Our AI Finds Ways to Slow/Reverse Atherosclerosis

WuXi NextCODE AI used to identify and validate major new therapeutic approach to slow and even reverse atherosclerosis.

26 Aug 2019
See Details

Filter Year:

01 Oct 2019

Biologically-Validated A.I. Yields Breakthrough in Cardiovascular Disease

Researchers at U.S.-based WuXi NextCODE and the Yale School of Medicine published two new studies in the Journal of Experimental Medicine and Nature Metabolism on novel, artificial intelligence (A.I.) approaches that breathe new life into big data for complex diseases.

Read More
18 Jul 2019

Endothelial life discontinues without Erk

The mechanism of maintaining vascular endothelial identity and integrity is largely unknown. In the issue of JEM, Richard et al. discover essential roles of ERK1/2 in maintaining endothelial homeostasis and its deletion-related serious defects in multiple tissues and organs.

Read More
26 Aug 2019

Transforming endothelial cells in atherosclerosis

Cells contributing to atherosclerotic disease are highly plastic and can shift their phenotype in a changing microenvironment. A study in Nature Metabolism now reveals that transforming growth factor-β (TGF-β) can transform endothelial cells into pro-inflammatory cells and that inhibition of TGF-β-receptor signalling in the endothelium can reverse atherosclerosis in mice.

Read More
19 Jun 2019

New Approaches to the Old Hunt for NASH Therapies

In this webinar experts from across the pharma field discuss potential new targets and approaches for NASH therapy, and where the field will go in the near future.

Read More
27 Mar 2019

Five-Year Super Successes in Genomics and Precision Medicine

WuXi NextCODE has grown over four years into a global genomic data and insights company that powers drug and diagnostic development with biopharma and medical center partners.

Read More
13 Jun 2019

Yale and WuXi NextCODE Use AI to Predict Phenotypes In Vivo

Study experimentally validates pioneering artificial intelligence strategy for the life sciences, accurately projecting complex disease processes using modest sets of gene expression data

Read More
25 Apr 2019

The Rise of Population-scale Genomic Projects for Pharma R&D Investments

With the announced $400 million investment from global investors including the Irish sovereign fund, WuXi NextCODE announced that GMI would whole genome sequence and collect detailed medical data on 400,000 Irish volunteers covering 60 major diseases, partnering with life sciences companies to analyse the data for insights.

Read More
05 Apr 2019

Unicorn startup trawls databases for protective genetic modifiers

Startup aims to identify disease modifying genes in people with milder than expected phenotypes as starting points for drug discovery programs.

Read More
13 Feb 2019

The 100 Leading Pioneers Of AI Drug Development

Forbes discusses the impact of AI on drug development as our executive leader, Thomas Chittenden, is featured in Deep Knowledge Analytics' "Top-100 AI Leaders in Drug Discovery and Advanced Healthcare."

Read More
12 Apr 2019

Specialized Metrics To Properly Assess AI-Pharma Startups

Although there are about 150 AI companies in the Drug Discovery space, very few of them are capable of building end-to-end solutions. Companies such as WuXi NextCODE, BenevolentAI, DeepMind Health, and Insilico Medicine are leaders in this area.

Read More
15 Jan 2019

Using Powered Cohorts to Speed Drug Discovery and Development

With the recent acquisition of Genomics Medicine Ireland (GMI, in Dublin), WuXi NextCODE is realizing the vision of turning advancements in genomics into improvements in drug discovery and ultimately population health, providing benefit to patients around the world.

Read More